Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The role and actions of the precision medicine for aggressive lymphoma (PMAL) consortium

Andrew Davies • 9 Jun 2016
EHA 2016
Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma

Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK describes the role and actions of the precision medicine for aggressive lymphoma (PMAL) consortium. Designed to be a collaboration between academia and industry, aims include optimizing diagnostic and stratification of patients with diffuse large B-Cell lymphoma (DLBCL). PMAL includes a network of individuals looking at transcriptome technology for use in DLBCL, optimizing signatures, identifying endotypes and mutation screening, among many other areas. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
Economic burden of CAR-T therapy from a UK perspective
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals